184 related articles for article (PubMed ID: 8996121)
1. Value of molecular monitoring during the treatment of chronic myeloid leukemia: a Cancer and Leukemia Group B study.
Stock W; Westbrook CA; Peterson B; Arthur DC; Szatrowski TP; Silver RT; Sher DA; Wu D; Le Beau MM; Schiffer CA; Bloomfield CD
J Clin Oncol; 1997 Jan; 15(1):26-36. PubMed ID: 8996121
[TBL] [Abstract][Full Text] [Related]
2. Persistence of dormant leukemic progenitors during interferon-induced remission in chronic myelogenous leukemia. Analysis by polymerase chain reaction of individual colonies.
Talpaz M; Estrov Z; Kantarjian H; Ku S; Foteh A; Kurzrock R
J Clin Invest; 1994 Oct; 94(4):1383-9. PubMed ID: 7929813
[TBL] [Abstract][Full Text] [Related]
3. Southern technique and cytogenetics are complementary and must be used together in the evaluation of Ph1, M-BCR positive chronic myeloid leukemia (CML) patients treated with alpha interferon (IFN-alpha).
Steegmann JL; Requena MJ; Casado LF; Pico M; Peñarrubia MJ; Ferro MT; Resino M; Fernandez-Rañada JM
Am J Hematol; 1996 Nov; 53(3):169-74. PubMed ID: 8895687
[TBL] [Abstract][Full Text] [Related]
4. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.
Merx K; Müller MC; Kreil S; Lahaye T; Paschka P; Schoch C; Weisser A; Kuhn C; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
Leukemia; 2002 Sep; 16(9):1579-83. PubMed ID: 12200666
[TBL] [Abstract][Full Text] [Related]
5. Quantitative real-time RT-PCR monitoring of BCR-ABL in chronic myelogenous leukemia shows lack of agreement in blood and bone marrow samples.
Stock W; Yu D; Karrison T; Sher D; Stone RM; Larson RA; Bloomfield CD
Int J Oncol; 2006 May; 28(5):1099-103. PubMed ID: 16596225
[TBL] [Abstract][Full Text] [Related]
6. Quantification of the breakpoint cluster region rearrangement for clinical monitoring in Philadelphia chromosome-positive chronic myeloid leukemia.
Verschraegen CF; Talpaz M; Hirsch-Ginsberg CF; Pherwani R; Rios MB; Stass SA; Kantarjian HM
Blood; 1995 May; 85(10):2705-10. PubMed ID: 7742530
[TBL] [Abstract][Full Text] [Related]
7. Molecular response of CML patients treated with interferon-alpha monitored by quantitative Southern blot analysis. German chronic myeloid leukaemia (CML) Study Group.
Reiter A; Skladny H; Hochhaus A; Seifarth W; Heimpel H; Bartram CR; Cross NC; Hehlmann R
Br J Haematol; 1997 Apr; 97(1):86-93. PubMed ID: 9136945
[TBL] [Abstract][Full Text] [Related]
8. Cytogenetic response to alpha-interferon is predicted in early chronic phase chronic myeloid leukemia by M-bcr breakpoint location.
Elliott SL; Taylor KM; Taylor DL; Rodwell RL; Williams BF; Shuttlewood MM; Wright SJ; Eliadis PE; Bunce IH; Frost TJ
Leukemia; 1995 Jun; 9(6):946-50. PubMed ID: 7596182
[TBL] [Abstract][Full Text] [Related]
9. Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission.
Paschka P; Müller MC; Merx K; Kreil S; Schoch C; Lahaye T; Weisser A; Petzold A; König H; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
Leukemia; 2003 Sep; 17(9):1687-94. PubMed ID: 12970765
[TBL] [Abstract][Full Text] [Related]
10. [Use of cytogenetic and molecular biology in the detection of chronic myeloid leukemia].
Michalová K; Zemanová Z; Haskovec C; Rypácková B; Brdicka R
Cas Lek Cesk; 1992 Dec; 131(24-25):729-32. PubMed ID: 1288873
[TBL] [Abstract][Full Text] [Related]
11. Molecular monitoring of residual disease in chronic myelogenous leukemia patients after therapy.
Hochhaus A; Reiter A; Skladny H; Reichert A; Saussele S; Hehlmann R
Recent Results Cancer Res; 1998; 144():36-45. PubMed ID: 9304705
[TBL] [Abstract][Full Text] [Related]
12. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
13. Rearrangement of BCR genes in malignant lymphoma.
Cheng G; McLeish W; Huebsch L; Drouin J; van der Jagt R; Tittley P; Markman S; Aye MT; Burns B
Leukemia; 1992 Jun; 6(6):553-5. PubMed ID: 1602794
[TBL] [Abstract][Full Text] [Related]
14. Molecular basis for therapeutic decisions in chronic myeloid leukemia patients after allogeneic bone marrow transplantation.
Román J; Alvarez MA; Torres A
Haematologica; 2000 Oct; 85(10):1072-82. PubMed ID: 11025600
[TBL] [Abstract][Full Text] [Related]
15. Use of quantitative polymerase chain reaction to monitor residual disease in chronic myelogenous leukemia during treatment with interferon.
Lion T; Gaiger A; Henn T; Hörth E; Haas OA; Geissler K; Gadner H
Leukemia; 1995 Aug; 9(8):1353-60. PubMed ID: 7643624
[TBL] [Abstract][Full Text] [Related]
16. Limited clinical value of regular bone marrow cytogenetic analysis in imatinib-treated chronic phase CML patients monitored by RQ-PCR for BCR-ABL.
Ross DM; Branford S; Moore S; Hughes TP
Leukemia; 2006 Apr; 20(4):664-70. PubMed ID: 16482210
[TBL] [Abstract][Full Text] [Related]
17. [Molecular biology follow-up of interferon therapy in patients with chronic myeloid leukemia].
Iványi JL; Marton E; Kereskai L; Kiss Z; Pajor L
Orv Hetil; 2000 Nov; 141(47):2527-33. PubMed ID: 11143285
[TBL] [Abstract][Full Text] [Related]
18. Molecular characterization of a variant Ph1 translocation t(9;22;11) (q34;q11;q13) in chronic myelogenous leukemia (CML) reveals the translocation of the 3'-part of BCR gene to the chromosome band 11q13.
Koduru PR; Goh JC; Pergolizzi RG; Lichtman SM; Broome JD
Oncogene; 1993 Dec; 8(12):3239-47. PubMed ID: 8247527
[TBL] [Abstract][Full Text] [Related]
19. Molecular methods to detect the Philadelphia chromosome.
Hooberman AL; Westbrook CA
Clin Lab Med; 1990 Dec; 10(4):839-55. PubMed ID: 2272177
[TBL] [Abstract][Full Text] [Related]
20. Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases.
Schoch C; Schnittger S; Bursch S; Gerstner D; Hochhaus A; Berger U; Hehlmann R; Hiddemann W; Haferlach T
Leukemia; 2002 Jan; 16(1):53-9. PubMed ID: 11840263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
